Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Maintenance Therapy in Advanced Pancreatic Cancer
NCT07600268Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic cancer (PC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: 1-Year Overall Survival Rate. Started Aug 2025; status: recruiting.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07600268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600268.